Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 5/20 | 0.38 |
| ▸ | SPR | P35270 | 3/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024749 | 0.84 | CNR1 (0.47) | CNR1ALDH1A1CA12CA1CA2 | |
| SCHEMBL6025464 | 0.79 | F11 (0.44) | CNR1ALDH1A1CA12CA1CA2 | |
| SCHEMBL6025849 | 0.75 | KMO (0.47) | ALDH1A1 | |
| SCHEMBL6025253 | 0.69 | CNR1 (0.48) | CNR1CA12CA1CA2CA9 | |
| SCHEMBL6025637 | 0.68 | CNR1 (0.53) | CNR1CCKAR | |
| SCHEMBL5113110 | 0.67 | CNR1 (0.51) | CNR1ALDH1A1CA12CA1CA2 | |
| SCHEMBL11602608 | 0.66 | CHRM4 (0.44) | CNR1CA12CA1CA2CA9 | |
| SCHEMBL23884905 | 0.65 | F11 (0.62) | CNR1ALDH1A1CA12CA1CA2 | |
| SCHEMBL8161869 | 0.65 | CA12 (0.72) | CA12CA1CA2CA9CA7 | |
| SCHEMBL9954295 | 0.65 | ALDH1A1 (0.44) | CNR1ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| EP-1638570-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| WO-2004110453-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885ALDH1A1 1683/4885CA12 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.